Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Heart Journal. Quality of Care and Clinical Outcomes Année : 2022

Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses

Maroua Mimouni
  • Fonction : Auteur
Jerome Frenkiel
  • Fonction : Auteur
Cristina Avendano-Solá
  • Fonction : Auteur
Jose Gonzalez-Juanatey
  • Fonction : Auteur
Emile Ferrari
Gilles Lemesle
Etienne Puymirat
Laurence Berard
Marine Cachanado
Joan Albert Arnaiz
Manuel Martínez-Sellés
  • Fonction : Auteur
Albert Ariza-Solé
Gonzalo Calvo
Nicolas Danchin
Sandra Paco
  • Fonction : Auteur
Elodie Drouet
Helene Abergel
  • Fonction : Auteur
Alexandra Rousseau
  • Fonction : Auteur
Tabassome Simon
Philippe Gabriel Steg

Résumé

Abstract Aims To estimate the cost–effectiveness and cost–utility ratios of a restrictive vs. liberal transfusion strategy in acute myocardial infarction (AMI) patients with anaemia. Methods and results Patients (n = 666) with AMI and haemoglobin between 7–8 and 10 g/dL recruited in 35 hospitals in France and Spain were randomly assigned to a restrictive (n = 342) or a liberal (n = 324) transfusion strategy with 1-year prospective collection of resource utilization and quality of life using the EQ5D3L questionnaire. The economic evaluation was based on 648 patients from the per-protocol population. The outcomes were 30-day and 1-year cost-effectiveness, with major adverse cardiovascular events (MACEs) averted as the effectiveness outcome. and a 1-year cost–utility ratio. The 30-day incremental cost–effectiveness ratio was €33 065 saved per additional MACE averted with the restrictive vs. liberal strategy, with an 84% probability for the restrictive strategy to be cost-saving and MACE-reducing (i.e. dominant). At 1 year, the point estimate of the cost–utility ratio was €191 500 saved per quality-adjusted life year gained; however, the cumulated MACE was outside the pre-specified non-inferiority margin, resulting in a decremental cost–effectiveness ratio with a point estimate of €72 000 saved per additional MACE with the restrictive strategy. Conclusion In patients with AMI and anaemia, the restrictive transfusion strategy was dominant (cost-saving and outcome-improving) at 30 days. At 1 year, the restrictive strategy remained cost-saving, but clinical non-inferiority on MACE was no longer maintained. Trial Registration ClinicalTrials.gov Identifier: NCT02648113. One sentence summary The use of a restrictive transfusion strategy in patients with acute myocardial infarction is associated with lower healthcare costs, but more evidence is needed to ascertain its long-term clinical impact.
Fichier non déposé

Dates et versions

hal-04002568 , version 1 (23-02-2023)

Identifiants

Citer

Isabelle Durand-Zaleski, Gregory Ducrocq, Maroua Mimouni, Jerome Frenkiel, Cristina Avendano-Solá, et al.. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses. European Heart Journal. Quality of Care and Clinical Outcomes, 2022, ⟨10.1093/ehjqcco/qcac029⟩. ⟨hal-04002568⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More